NeoGenomics, Inc. (NEO) vs Veracyte, Inc. (VCYT)
- NeoGenomics, Inc. NEO 16.65 −3.48%
- Veracyte, Inc. VCYT 43.12 −2.86%
NeoGenomics, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. Veracyte, Inc. is the larger, with a market value of $3.6B against $2.2B — 1.6× the size. NeoGenomics, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 29.9×. Veracyte, Inc. grew revenue faster over the last twelve months: 17.3% against 11.2%. Veracyte, Inc. has the higher net margin (20.4% vs −6.77%) and the higher return on invested capital (7.32% vs −4.20%). Across the 18 metrics below, Veracyte, Inc. leads on 16 and NeoGenomics, Inc. on 2.
Valuation
Profitability
| Metric | NEO | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 43.92% | 71.71% | 50.89% |
| Operating margin | (8.93%) | 18.82% | (8.57%) |
| Net margin | (6.77%) | 20.37% | (6.37%) |
| Free cash flow margin | (0.69%) | 29.54% | 0.00% |
| Return on equity | (6.33%) | 8.77% | (2.92%) |
| Return on assets | (3.78%) | 8.09% | (6.71%) |
| Return on invested capital | (4.20%) | 7.32% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack